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Abstract
Three acidic phospholipases A
2
 from Indian cobra (Naja naja naja) venom inhibited platelet aggregation in platelet rich plasma
induced separately by ADP, collagen and epinephrine with different potencies. The order of inhibition was epinephrine > col-
lagen > ADP. They did not inhibit platelet aggregation induced by arachidonic acid (10 µM). The inhibition was dependent on
concentration of the protein and the time of incubation of the phospholipases A
2
 with platelet rich plasma. Parabromophenacyl
bromide modified PLA
2
 enzymes lost their enzymatic activity as well as platelet aggregation inhibition activity suggesting the
involvement of catalytic function in platelet aggregation inhibitory activity. (Mol Cell Biochem 219: 39–44, 2001)
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Introduction




) are known to exhibit
a broad spectrum of pharmacological activities such as neu-
rotoxicity, cardiotoxicity, cytotoxicity, effects on platelet
aggregation, hemolytic, pro- and anticoagulant, edema induc-
ing and hypotensive [1, 2]. Phospholipases A
2
 exhibiting
these activities, in synergism with other venom protein may
help in the acquisition and/digestion of the prey under natu-
ral conditions. The venom PLA
2
 provides useful tools for un-
derstanding molecular events in normal physiology as well
as new targets of drug development for clinical use.
Platelet aggregation is an important cellular process in
thrombosis and hemostasis [3]. Several snake venom PLA
2
potentiates initiation and/inhibition of platelet aggregation.
Acidic phospholipases are also among the PLA
2
, which in-
terfere in platelet functions. The role of catalytic activity of
the PLA
2
 enzyme in the inhibition of agonist induced platelet
aggregation has been addressed by several groups [2, 4–11].
The results are varying from enzyme to enzyme suggest-
ing that the individual PLA
2
 effect inhibition of platelet
aggregation differently. Present paper deals with role of
catalytic activity of phospholipases A
2
 from Naja naja naja
venom on platelet aggregation induced by agonists such as
epinephrine, collagen, adenosine diphosphate (ADP) and
arachidonic acid.
Materials and methods
Arachidonic acid, ADP, collagen and epinephrine were pur-
chased from Sigma Chemical Co. St. Louis, USA. 1-nitroso-
2-naphthol was purchased from Sigma Chemical Co. St. Louis,
USA. Phosphatidyl choline (PC) was prepared from hen’s egg
yolk according to the method of Singleton et al. [12]. Human
blood samples were from healthy volunteers from Department
of studies in Biochemistry, Manasagangothri, Mysore, India
and Central Food Research Institute (CFTRI) Mysore, India.
All other chemicals used were of analytical grade.













ified from Naja naja naja venom as described in our previ-
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ous paper [13]. Indian cobra venom was fractionated on a
CM-Sephadex C-25 column according to the method of Bhat
and Gowda [14]. This resolved the venom into 14 peaks. The





 was resolved into three peaks upon gel filteration







. The enzyme elution profile showed













gave several coomassie blue stained bands on native
– PAGE. This fraction was resolved into five peaks on a QAE-






































 activity was assayed by estimating the free
fatty acid released as described by Bhat and Gowda [14], us-
ing egg phosphatidyl choline as substrate. The incubation
mixture contained 1 µM of egg phosphotidyl choline, 0.2 ml
of diethyl ether, 0.05 M Tris-HCl buffer (pH 7.5) 40 mM
Ca2+and 0.2 ml of enzyme (2–5 µg) in 1 ml. The free fatty
acid released was extracted as cobalt soap and was complexed
with 1-nitroso 2-naphthol and estimated colorimetrically. Ac-
tivity is expressed as nmoles of free fatty acid released/min/
mg of protein.
Isolation of platelets
Human blood was collected from the vein of healthy non-
smoker volunteers who had not taken any medication for at
least the previous 2 weeks. Nine volumes of blood was col-
lected into one volume of acid citrate dextrose (93 mM So-
dium citrate, 7 mM citric acid and 140 mM glucose, pH 6.5)
and immediately centrifuged for 10 min at 90 × g at room tem-
perature (25°C). The supernatant obtained was collected as
platelet rich plasma (PRP). Homologous platelet poor plasma
(PPP) was prepared by recentrifugation of the remaining
blood for 15 min at 500 × g at 25°C. The platelet concentra-
tion of PRP was adjusted with PPP to 2,25,000 ±  25,000
platelets/µl. The PRP was kept at 37°C and was used within
3 h after preparation. All the above preparation was carried
out using plasticware or siliconized glassware.
Platelet aggregation
Platelet aggregation was studied by the turbidometric method
of Born [15], using a chronolog dual channel aggregometer
connected to omniscribe dual pen recorder to record the light
transmission as a function of time. Briefly, the action of ago-
nist on platelets is measured by increased light transmission.
When a platelet aggregating agent (agonist) is added to PRP,
the platelet clump and PRP becomes progressively clear,
showing increased light transmission with time. For concen-
tration dependent platelet aggregation studies, different con-













were preincubated separately with PRP with con-
stant stirring for 2 min.
 
For time dependent platelet aggrega-
tion studies, aliquots of PRP were preincubated with each of
the above mentioned enzymes (10 µg/ml) for different time
intervals (2–60 min). Platelet aggregation of treated PRP was
then initiated by addition of ADP (76 µM), collagen (~ 2 µg/
ml), epinephrine (22 µM), and arachidonic acid (10 µM) sepa-
rately. Percent inhibition was calculated assuming the values
of control (without any aggregation inhibitor) to be 100%.




Chemical modification of PLA
2
 by p-bromophenacyl bro-
mide (p-BPB) was carried out as described by Condrea et al.
[16]. One hundred microliters of 40 mM p-BPB in acetone
were added to 3 ml of PLA
2
 solution (0.5 mg/ml, in 0.05 M
Tris-HCl buffer, pH 7.5). The reaction was allowed to pro-
ceed for 40 min, and then acidified with glacial acetic acid
to pH 4.0 to stop the reaction. Excess of reagent was removed
by dialysing against 0.05 M Tris-HCl buffer pH 7.5.
Determination of protein
Protein was estimated according to the method of Lowry et











 were purified to homogeneity using
combinations of ion exchange and gel filteration chromatog-
raphies [13]. The PLA
2





 of the three PLA
2 
isoforms are
given in Table 1.
The effect of these PLA
2
 isoforms in platelet aggregation
was determined using PRP sample. All three PLA
2
 isoforms
inhibits platelet aggregation induced by each of the agonist
epinephrine, collagen and ADP. Figure 1 represents a typi-
cal inhibition pattern of platelet aggregation induced by all




. The inhibition is dose de-
pendent for all the three agonist induced platelet aggregation;
with ADP and collagen induced platelet aggregation, maxi-
mum inhibition was observed at 24 µg/ml, whereas with
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epinephrine induced platelet aggregation, maximum inhibi-
tion was observed even at 9 µg/ml. Similar pattern of dose




 isoforms inhibited platelet aggregation
induced by epinephrine at low protein concentration on the
other hand they required high protein concentration to inhibit
platelet aggregation induced by ADP and collagen. Interest-
ingly these three PLA
2
 isoforms failed to inhibit platelet ag-
gregation induced by arachidonic acid.
The inhibition of agonists induced platelet aggregation by
inhibitors depends on the duration of preincubation time of
platelets with inhibitors before inducing aggregation with
agonist. Figure 2 shows the effect of preincubation time with
platelets at low concentration of all PLA
2
 isoforms. Pre-
incubation effect was observed with ADP induced platelet
aggregation. The inhibition of platelet aggregation increased
with preincubation time. Among all three isoforms, NN-I
2e
showed higher inhibition. Time dependent aggregation stud-




 isoforms inhibits platelet aggregation in a
dose dependent manner induced by ADP (Fig. 3A), collagen
(Fig. 3B) and epinephrine (Fig. 3C). Maximum inhibition of
20–30% was observed at 24 µg/ml of PLA
2
 isoforms with ADP
induced platelet aggregation (Fig. 3A), whereas collagen in-
duced platelet aggregation was inhibited to 70–100% at the
same concentration. Much stronger inhibition of 60–100% was
observed with 9 µg/ml of PLA
2
 isoforms with epinephrine









inhibited platelet aggregation induced by collagen and ep-









 isoforms exhibit/showed similar affinity for
phospholipid and its hydrolysing activity. The specific activ-
ity was ranging from 9–16 µM of fatty acid released/min/mg
of protein. The maximum concentration of protein used in
ADP and collagen induced platelet aggregation inhibition
studies was 24 µg and less in epinephrine induced platelet
aggregation. At these protein concentrations the amount of
Table 1. Comparative phospholipaseA
2








Specific activity* Km (µM) Vmax (µM)
NN-I2c-PLA2 9.0 ± 0.3 0.32 0.49
NN-I2d-PLA2 13.0 ± 0.5 0.42 0.74
NN-I2e-PLA2 16 ± 0.5 0.38 0.94
*Specific activity is expressed in terms of µM of fatty acid released/min/
mg of protein. Data are mean values ± S.E.M. obtained with 6 experiments.
Fig. 1. Inhibition of ADP (A), collagen (B) and epinephrine (C) induced
platelet aggregation by NN-I2e–PLA2. PRP was incubated with NN-I2e –PLA2
(0–24 µg/ml) for 2 min at 37°C. Inhibition of platelet aggregation initiated
by the addition of ADP (76 µM), collagen (~  2 µg/ml), epinephrine (22 µM)
was recorded.
Fig. 2. Inhibition of platelet aggregation by phospholipase A2 NN-I2c (l), NN-
I2d (O) AND NN-I2e (t) with time. Each PLA2 (10 µg/ml) was preincubated
with PRP for different time intervals at 37°C. Platelet aggregation was ini-
tiated by the addition of ADP (76 µ M). Each value represents mean ± S.E.M.
of 6 experiments.
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fatty acid released was less than 1 µM when phosphatidyl
choline was used as the substrate. An equivalent amount of
lysophospholipid was also expected to be released.
We examined the role of catalytic activity in the agonists
induced platelet aggregation. p-BPB inhibits PLA
2
 activity
by modifying Histidine-48 residue which is essential for the
catalytic function of PLA
2
 [18]. In the present investigation
modification of all the PLA
2
 isoforms by p-BPB resulted in
the complete loss of enzyme activity (Table 2). The chemi-
cally modified PLA
2
 isoforms failed to inhibit platelet aggre-
gation induced by the three agonist. Figure 4 represents the




 on the inhibition of platelet
aggregation induced by ADP, collagen and epinephrine.
Discussion
Platelet aggregation is induced by large number of physi-
ological agents such as ADP, serotonin, epinephrine, collagen,
thrombin and A23187 ionophore [18]. The platelets interact
through a specific receptor mechanism, which mediates shape
change, aggregation and release reaction. In the present in-
Fig. 3. Effect of phospholipase A2 NN-I2c (l), NN-I2d (O) AND NN-I2e (t)
concentration on (A) ADP (B) collagen (C) epinephrine induced platelet
aggregation. Different concentrations of PLA2 were separately incubated
with PRP for 2 min at 37°C. The platelet aggregation initiated by addition
of ADP (76 µM), Collagen (~ 2 µg/ml), epinephrine (22 µM) separately was
recorded. Each value represents mean ± S.E.M. of 6 experiments.
Table 2. PLA
2





NN-I2c-PLA2 8.7 ± 0.4  0.1 ± 0.06
NN-I2d-PLA2 12.8 ± 0.6  0.3 ± 0.05
NN-I2e-PLA2 16.5 ± 0.3  0.5 ± 0.1
*Specific activity is expressed in terms of µM of fatty acid released/min/
mg of protein. Data are mean values ± S.E.M. obtained with 6 experiments.
Fig. 4.
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vestigation the effect of PLA
2
 isoforms on platelet aggrega-
tion induced by agonist such as ADP, collagen, epinephrine
and arachidonic acid was carried out. Platelet aggregation in
response to ADP and epinephrine release serotonin and nucleo-
tides mostly ADP, which further initiates aggregation [19–21].
When collagen is the stimulating agent, aggregation is caused
by adhesion to platelets followed by release of platelet serot-
onin and ADP [22–23]. Arachidonic acid induced platelet ag-
gregation is due to the inhibition of thromboxane synthase by
its metabolites of the lipoxygenase pathway [24], or due to
interference with agonist receptor interaction [25].
Snake venoms are a source of toxins which interfere/modify
the process of hemostasis. [3, 26]. The phospholipases
 
of the
venoms are one of the major components associated with
this function. Based on their effects on the platelet function,
venom PLA
2
 enzymes can be divided into three major classes:
(a) initiate platelet aggregation [8, 11], (b) inhibit platelet ag-
gregation [6, 26–28] and (c) exhibit biphasic effects (initiate
aggregation at low concentration or with short incubation
time but inhibit aggregation at high concentration or with
long incubation time) [11, 29].
The three acidic PLA
2
’s purified from Indian cobra Naja
naja naja venom, are catalytically highly active when com-
pared to the basic PLA
2
’s. So far no pharmacological prop-
erty associated with the acidic PLA
2
 have been reported. All









not induce aggregation of platelets but actively inhibited the
platelet aggregation induced by the agonists epinephrine,
collagen and ADP. The inhibition of platelet aggregation by
PLA
2
 isoforms is concentration dependent. Hence these PLA
2
isoforms do not belong to either group (a) or (c) therefore they
may be placed under group (b).
An acidic PLA
2
 from Agkistrodon acutus venom initiates
aggregation by enzymatic hydrolysis of platelet phospholi-
pids and inhibits platelet aggregation in PRP which was not
dependent on protein concentration [4]. Platelet aggregation





 activity [2]. However, the inhibition exhibited
by the three isoforms of PLA
2
 isolated from Naja naja naja






 may cause a limited hydrolysis of membrane
phospholipids and release arachidonic acid [30–31]. The ar-
achidonate is an agonist, which can induce platelet aggrega-
tion/enhance the aggregation induced by the agonist mentioned
above [32]. In contrast, arachidonate and lysophosphatidyl-
choline can also, serve as antagonist of platelet aggregation
induced by collagen [31]. The lysophosphatidylcholine formed
by the digestion of phospholipids by the PLA
2
 enzymes also
have effects on the platelet [33]. Therefore the PLA
2
 should
have served as agonist of platelet aggregation as their action
results in the formation of arachidonate and lysophosphotides
[32]. However all the isoforms of PLA
2
 investigated in this
study inhibited the platelet aggregation induced by the agonists
epinephrine, collagen and ADP.
The pattern of inhibition brought about by PLA
2
 isoforms
appears to differ depending on the agonists responsible for
platelet aggregation. When identical concentrations of PLA
2
isoforms are used against the platelet aggregation induced by
ADP and collagen, a dose dependent platelet aggregation
inhibition was observed (Figs 3A and 3B). The extent of in-
hibition was not comparable especially at higher concen-
trations of the isoforms of PLA
2
. The present study indicates
the result of PLA
2
 action on platelets which may not be due to
release of agonists such as arachidonate and lysophosphotides,
but due to modification brought about on the surface of the
platelets. The inhibition could be due to the reduced pseudo-
pod induction in the presence of the inhibitor [34].
The platelet aggregation induced by the third agonist in this
study, epinephrine is also inhibited by the PLA
2
 isoforms
from Naja naja naja venom. The amount of PLA
2
 isoforms
present to inhibit platelet aggregation is much lower when
compared to the other two agonists used ADP and collagen
(Figs 3A–3C). Therefore the amount of arachidonate and
lysophosphatides that may be released by these PLA
2
 iso-
forms from the platelets should be lower and should enhance
platelet aggregation. Since arachidonate can bring about the
platelet aggregation at a concentration range of 0.1–2 µM
[32], the PLA
2
 concentration used in the study are expected
to release arachidonate in this range. It can be seen from the
platelet aggregation inhibition by the PLA
2
 isoforms when
ADP (Fig. 3A) is the agonist, it is about 10% at a PLA
2
 con-
centration of 12 µg. On the other hand the same inhibitory
effect is observed at half the concentration of the PLA
2
 when
epinephrine (Fig. 3C) is used as the agonist. But the extent
of inhibition of aggregation observed was markedly higher
when compared to the inhibition of platelet aggregation in-
duced by collagen and ADP. This indicates that the platelet
aggregation inhibited by the PLA
2
 isoforms is not due to the
release of arachidonate and lysophosphotides but due to spe-
cific modification of the platelets by the catalytic activity of
the PLA
2
 isoforms. Further, if the fluidity of the membrane
is decreased it can lead to reduced interaction among the
platelets [35, 36].
Chemical modification of the PLA
2
 by p-BPB results in
the modification of histidine-48 of the PLA
2
 enzymes. Such
a modification has been demonstrated to abolish the PLA
2
activity of the enzyme [16, 37]. In our study the chemical
modification of all the three isoforms of PLA
2
 by p-BPB
resulted in the loss of catalytic activity. The chemically modi-
fied PLA
2
 isoforms lost their platelet aggregation activity
induced by epinephrine, collagen and ADP. This further
strengthens the involvement of catalytic function in plate-
let aggregation process. The evidences present in this pa-
per clearly indicate that (a) PLA
2
 alters the platelets by their
catalytic function, (b) this modification is differentially rec-
44
ognized in the aggregation process induced by the different
agonists.
Acknowledgements
We thank Dr. B.S. Vishwanath, Reader, DOS In Biochemis-
try, University of Mysore for his valuable suggestions in the
discussion of the paper. L.M.S.R. acknowledges the finan-
cial assistance from University Grants Commission, New
Delhi, India.
References
1. Kini RM, Evans HJ: A model to explain the pharmacological effects
of snake venom phospholipases A2. Toxicon 27: 613–635, 1989
2. Huang HC, Yeh HI, Ouyang C: Mechanism of the platelet aggregation
inhibitor purified from Agkistrodon halys (mamushi) snake venom.
Toxicon 22: 243–251, 1984
3. Kini RM, Evans HJ: Effects of snake venom proteins on blood plate-
lets. Toxicon 28: 1387–1421, 1990
4. Chen RH, Chen YC: Isolation of an acidic phospholipase A2 from the
venom of Agkistrodon acutus (Five pace snake) and its effect on platelet
aggregation. Toxicon 27: 675–682, 1989
5. Kini RM, Evans HJ: Correlation between the enzymatic activity, anti-
coagulant and antiplatelet effects of phospholipase A2 isoenzyme from
Naja nigricollis venom. Thromb Haemostat 60: 170–173, 1988
6. Li YS, Liu KF, Wang QC, Ran YL, Tu GC: A platelet function inhibi-
tor purified from Vipera russelli siamensis (Smith) snake venom.
Toxicon 23: 895–903, 1985
7. Ouyang C, Huang TF: Effect of the purified phospholipases A2 from
snake and bee venoms on rabbit platelet function. Toxicon 22: 705–
718, 1984
8. Ouyang C, Teng CM, Chen YC: Properties of fibrinogen degrada-
tion products produced by α and β-fibrinogenases of Trimeresurus
mucrosquamatus snake venom. Toxicon 17: 121–126, 1979
9. Prasad BN, Kemparaju K, Bhatt KGS, Gowda TV: A platelet aggrega-
tion inhibitor phospholipase A2 from Russell’s viper (Vipera russelli)
venom: Isolation and characterization. Toxicon 34: 1173–1185, 1996
10. Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y: Venom from south-
ern copperhead snake (Agkistrodon contortrix contortrix) II. A unique
phospholipase A2 that induces platelet aggregation. Toxicon 26: 199–
206, 1988
11. Teng CM, Kuo YP, Lee LG, Ouyang C: Effect of cobra venom phos-
pholipase A2 on platelet aggregation in comparison with those produced
by arachidonic acid and lysophosphatidylcholine. Thromb Res 44:
875–886, 1986
12. Singleton WS, Gray MS, Brown ML, White JL: Chromatographically
homogenous lecithin from egg phospholipids. J Am Oil Chem Soc 42:
53–56, 1965
13. Rudrammaji LMS, Gowda TV: Purification and characterization of
three Acidic, cytotoxic phospholipases A2 from Indian Cobra (Naja
naja naja) venom. Toxicon 36: 921–932, 1998
14. Bhat M, Gowda TV: Purification and characterization of myotoxic
phospholipase A2 from Indian cobra (Naja naja naja) venom. Toxicon
27: 861–874, 1989
15. Born GVR: Quantitative investigation into the aggregation of blood
platelets. J Physiol 162: 67–72, 1962
16. Condrea E, Fletcher JE, Rapuano BE, Yang CC, Rosenberg P: Effect of
modification of one histidine residue on the enzymatic and pharmaco-
logical properties of a toxic phospholipase A
2
 from Naja nigricollis
snake venom and less toxic phospholipases A2 from Haemachatus
haemachatus and Naja naja atra snake venoms. Toxicon 19: 61–71, 1981
17. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measure-
ment with the folin-phenol reagent. J Biol Chem 193: 265–275, 1951
18. Zucker MB: Platelet aggregation measured by photometric method.
Meth Enzymol 169: 117–133, 1989
19. Mills PCB, Robb IA, Roberts GCK: The release of nucleotides, 5-
hydroxy tryptamine and enzymes from human platelets during aggre-
gation. J Physiol 195: 715–729, 1968
20. O’Brien JRA: Comparison of platelet aggregation produced by seven
compounds and a comparison of their inhibitors. J Clin Path 17: 275–
281, 1964
21. Salzman EW, Chamberr DA, Neri LL: Possible mechanism of aggre-
gation of blood platelets by adenosine diphosphate. Nature 210: 167–
169, 1966
22. Hovig T: Aggregation of rabbit blood platelets produced in vitro by
saline ‘extracts’ of tendons. Thromb Diather Maemorrh 9: 248–263,
1963
23. Spaet TH, Zucker MB: Mechanism of platelet plug formation and role
of adenosine diphosphate. Am J Physiol 206: 1267–1274, 1964
24. Hamberg M, Svensskon J, Samuelsson B: Thromboxanes: A new group
of biologically active compounds derived from prostaglandin endo-
peroxides. Proc Natl Acad Sci USA 72: 2994, 1981
25. Fratantoni JC, Poindexter BJ: Characterization of the platelet response
to exogenous arachidonic acid. Thromb Res 22: 157–166, 1981
26. Li YS, Liu KF, Wang QC: Mechanism of action of the platelet func-
tion inhibitor purified from Vipera russeli siamensis snake venom.
Toxicon 24: 875–883, 1986
27. Laing GD, Kamiguti AS, Wilkinson MC, Lowe GM, Theakston RDG:
Characterization of a purified phospholipase A
2
 from the venom of the
Papuan black snake (Pseudechis papuanus). Biochim Biophys Acta
1250: 237–143, 1995
28. Kemparaju K, Krishnakanth TP, Veerabasappa gowda T: Purification
and characterization of a platelet aggregation inhibitor acidic phos-
pholipase A2 from Indian saw-scaled viper (Echis carinatus) venom.
Toxicon 35: 1659–1671, 1999
29. Kini RM, Evans HJ: Effect of phospholipase A2 enzymes on platelet
aggregation. In: Venom Phospholipase A2 Enzymes. Structure, Func-
tion and Mechanism. John Wiley and Sons, 1997, pp 369–387
30. Kanagi R, Koizumi K, Masuda T: Limited hydrolysis of platelet mem-
brane phospholipids on the proposed phospholipase susceptible domain
in platelet membrane. J Biol Chem 256: 1177–1182, 1981
31. Teng CM, Chen YH, Ouyang C: Biphasic effect on platelet aggrega-
tion by phospholipase A2 purified from Vipera russelli snake venom.
Biochim Biophys Acta 772: 393–402, 1984
32. Silver MJ, Smith JB, Ingerman C, Kocsis JJ: Arachidonic acid induced
platelet aggregation and prostaglandin formation. Prostaglandins 4:
863–866, 1973
33. Joist JH, Dolezel G, Cucuianu MP, Wishizawe EE, Mustard JF: Inhi-
bition and potentiation of platelet function by lysolecithin. Blood 49:
101, 1977
34. Feiyge MAH, Heemskerk JWM, Hornistra G: Membrane fluidity of
activated and nonactivated human blood platelets. Biochim Biophys
Acta 1025: 1173–1178, 1990
35. Shatil SJ, Anaya-Galimbodo R, Bennett J, Colman RW, Cooper RA:
Platelet hypersensitivity induced by cholesterol incorporation. J Clin
Invest 55: 636–643, 1975
36. Shatil SJ, Cooper RA: Membrane micro viscosity and human platelet
function. Biochemistry 15: 4832–4837, 1976
37. Fuly AL, Machado OLT, Alves EW, Carlini CR: Mechanism of inhibi-
tory action on platelet activation of a phospholipase A2 isolated from
Lacheis muta (Bushmaster) snake venom. Thromb Haemostat 78:
1372–1380, 1997
